name	nt_name	aa_name	multi_aa_name	multiaa_comb_mutation	start	vcf_gene	chrom_region	mutation_type	sequence_depth	sample_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao	reference_seq	variant_seq	viral_lineages	function_category	citation	comb_mutation	function_description	heterozygosity	clade_defining	who_variant	status	voi_designation_date	voc_designation_date	vum_designation_date
c.-3delA	c.-3delA				28270	N	intergenic		406	407						0	406	TA	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
c.C-25T	c.C-25T				241	orf1ab	5' UTR		407	407						0	407	C	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
c.G-56T	c.G-56T				210	orf1ab	5' UTR		407	407						0	407	G	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
c.G29742T	c.G*4358T				29742	intergenic	Stem-loop,3' UTR		403	407						0	403	G	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
c.G29781T	c.G*4397T				29781	intergenic	3' UTR		37	407						33	4	G	T	B.1.617.1					False	False	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.A5692S	c.G17074T	p.A5692S			17338	orf1ab	ORF1ab	MISSENSE	407	407			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	69	338	G	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D111D	c.T333C	p.D111D			21895	S	S	SILENT	402	407						0	402	T	C	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D377Y	c.G1129T	p.D377Y			29402	N	N	MISSENSE	407	407						0	407	G	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'P681R', 'Q1071H'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]"	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'L452R'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'L452R', 'E484Q'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617) showed a 1.85x increase  in binding (KD) relative to D614G. [exact variant list not provided in manuscript, is inferred fro common knowledge]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'T95I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	ACE2 receptor binding affinity	Li et al. (2020)		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	convalescent plasma binding	Gong et al. (2021)	'L452R'	2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	convalescent plasma binding	Gong et al. (2021)	'L452R', 'E484Q'	This variant combination (representing lineage B.1.617) showed a 1.22x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred fro common knowledge]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	convalescent plasma binding	Gong et al. (2021)	'T95I'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	convalescent plasma escape	Tada et al. (2021)	'L452R', 'E484Q'	Pseudotyped viruses for B.1.617 was 2.3-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	convalescent plasma escape	Wilhelm et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'P681R', 'Q1071H'	Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	convalescent plasma escape	Wilhelm et al. (2021)	'L452R'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	immunosuppression variant emergence	Landis et al. (2021)		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	syncytium formation	Kim et al. (2021)		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	tissue specific neutralization	Planas et al. (2021)		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oralâ€“nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	trafficking	Barrett et al. (2021)		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	trafficking	Daniloski et al. (2021)		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	trafficking	Esclera et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'P681R', 'Q1071H'	~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site). 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	trafficking	Kim et al. (2021)		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	trafficking	Kim et al. (2021)		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	trafficking	Ozono et al. (2020)		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	trafficking	Tada et al. (2021)	'P681R'	Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	trafficking	Zhang et l. (2020)		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	transmissibility	Tada et al. (2021)	'L452R'	Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	transmissibility	Tada et al. (2021)	'L452R', 'E484Q'	The combination caused a 3-fold increase in infectivity relative to D614G wild type. [compare to 3.5x for L452R alone]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	transmissibility	Tada et al. (2021)	'L452R', 'E484Q', 'P681R'	Normalized for particle number, on ACE2.293T cells showed that the B.1.617 spike protein was >2-fold increase in infectivity relative to D614G wild type.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'P681R', 'Q1071H'	Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'T95I', 'G142D', 'E154K', 'L452R', 'E484Q', 'P681R', 'Q1071H'	"Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	vaccine neutralization efficacy	Gong et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'P681R', 'Q1071H'	1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	vaccine neutralization efficacy	Gong et al. (2021)	'L452R', 'E484Q'	1.4x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	vaccine neutralization efficacy	Kuzmina et al. (2021)		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9â€“11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccinationâ€”mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	vaccine neutralization efficacy	Tada et al. (2021)	'L452R', 'E484Q'	Pseudotyped viruses for B.1.617 was 4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 5-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	vaccine neutralization efficacy	Wilhelm et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'P681R', 'Q1071H'	Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	vaccine neutralization efficacy	Wilhelm et al. (2021)	'L452R'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	vaccine neutralization efficacy	Yadav et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'P681R', 'Q1071H'	Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	vaccinee plasma binding	Gong et al. (2021)	'L452R'	1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	vaccinee plasma binding	Gong et al. (2021)	'L452R', 'E484Q'	This variant combination (representing lineage B.1.617) showed a 1.30x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.18x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred fro common knowledge]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	vaccinee plasma binding	Gong et al. (2021)	'T95I'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	viral load	Plante et al. (2020)		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	virion structure	Weissman et al. (2020)		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	virion structure	Yurkovetskiy et al. (2020)		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	407	407						0	407	A	G	B.1.617.1	virion structure	Zhang et al. (2020)		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E154K	c.G460A	p.E154K			22022	S	S	MISSENSE	405	407						0	405	G	A	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'G142D', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]"	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E154K	c.G460A	p.E154K			22022	S	S	MISSENSE	405	407						0	405	G	A	B.1.617.1	convalescent plasma escape	Schmidt et al. (2021)		Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E154K	c.G460A	p.E154K			22022	S	S	MISSENSE	405	407						0	405	G	A	B.1.617.1	convalescent plasma escape	Wilhelm et al. (2021)	'G142D', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E154K	c.G460A	p.E154K			22022	S	S	MISSENSE	405	407						0	405	G	A	B.1.617.1	trafficking	Esclera et al. (2021)	'G142D', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site). 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E154K	c.G460A	p.E154K			22022	S	S	MISSENSE	405	407						0	405	G	A	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'G142D', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E154K	c.G460A	p.E154K			22022	S	S	MISSENSE	405	407						0	405	G	A	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'T95I', 'G142D', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	"Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E154K	c.G460A	p.E154K			22022	S	S	MISSENSE	405	407						0	405	G	A	B.1.617.1	vaccine neutralization efficacy	Gong et al. (2021)	'G142D', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E154K	c.G460A	p.E154K			22022	S	S	MISSENSE	405	407						0	405	G	A	B.1.617.1	vaccine neutralization efficacy	Wilhelm et al. (2021)	'G142D', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E154K	c.G460A	p.E154K			22022	S	S	MISSENSE	405	407						0	405	G	A	B.1.617.1	vaccine neutralization efficacy	Yadav et al. (2021)	'G142D', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E2089D	c.G6267T	p.E2089D			6532	orf1ab	ORF1ab	MISSENSE	407	407			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	110	297	G	T	B.1.617.1					False	False	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'G142D', 'E154K', 'L452R', 'D614G', 'P681R', 'Q1071H'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]"	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'L452R', 'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617) showed a 1.85x increase  in binding (KD) relative to D614G. [exact variant list not provided in manuscript, is inferred fro common knowledge]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	antibody epitope effects	Sun et al. (2021)		>20% (ELISA significance threshold) drop in antibody binding by this variant against monoclonal antibody VH-Fc ab8.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	convalescent plasma binding	Gong et al. (2021)	'L452R', 'D614G'	This variant combination (representing lineage B.1.617) showed a 1.22x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred fro common knowledge]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	convalescent plasma escape	Greaney et al. (2021)		In 3 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,  E484Q shows a notably resistant profile, comparable to or even more resistant than E484K at  later time points (i.e. more resistant to immune cell somatic mutation evolution), see Figure 5a,b. Subject C 32 days post-infection showed >>10 fold reduction in neutralization, reducing to ~10-fold by day 104. Subject B 26 days post-infection showed ~10 fold reduction in neutralization, reducing to ~4x at day 113. Notably, Subject B also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 32,  and no E484K immune escape at day 104. Subject I 26 days post-infection showed ~10 fold reduction in neutralization, with no reduction in escape at day 102. Notably, Subject I also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 26,  and no E484K immune escape at day 102.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	convalescent plasma escape	Tada et al. (2021)	'L452R', 'D614G'	Pseudotyped viruses for B.1.617 was 2.3-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	convalescent plasma escape	Wilhelm et al. (2021)	'G142D', 'E154K', 'L452R', 'D614G', 'P681R', 'Q1071H'	Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	monoclonal antibody serial passage escape	Starr et al. (2021)		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	pharmaceutical effectiveness	Engelhart et al. (2021)		Bamlanivimab (LY-CoV555) lost ~20x binding against this isolated mutation. Casirivimab lost ~4x binding against this isolated mutation.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	symptom prevalence	Yadav et al. (2021)	'L452R', 'P681R'	Gross examination of 3+3 hamster lung specimens showed pronounced congestion and hemorrhages on days 5 and 7 post-infection in the case of the B.1.617.1 as compared with the B.1. The lung lesions with  the B.1 variant were minimal to mild whereas with B.1.617.1 they were moderate. For B.1 pneumonic changes were minimal to mild (inflammatory cell infiltration, focal consolidation and mild congestion). The pronounced changes (moderate to severe) with mononuclear infiltration in the alveolar interstitial space, interstitial septal thickening, consolidation and pneumocyte hyperplasia were observed with B.1.617.1 variant consistently.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	trafficking	Esclera et al. (2021)	'G142D', 'E154K', 'L452R', 'D614G', 'P681R', 'Q1071H'	~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site). 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	trafficking	Ferriera et al (2021)		This variant alone shows a 10x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	transmissibility	Tada et al. (2021)	'L452R', 'D614G'	The combination caused a 3-fold increase in infectivity relative to D614G wild type. [compare to 3.5x for L452R alone]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	transmissibility	Tada et al. (2021)	'L452R', 'P681R', 'D614G'	Normalized for particle number, on ACE2.293T cells showed that the B.1.617 spike protein was >2-fold increase in infectivity relative to D614G wild type.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'G142D', 'E154K', 'L452R', 'D614G', 'P681R', 'Q1071H'	Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'T95I', 'G142D', 'E154K', 'L452R', 'D614G', 'P681R', 'Q1071H'	"Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	vaccine neutralization efficacy	Ferreira et al. (2021)	'L452R'	Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484Q had a ~5x drop in neutralization (vs ~10x for E484K). When E484Q and L452R were combined, the fold change was significant, but similar to that of L452R alone (~2x), suggesting no evidence for an additive effect [perhaps even E484Q effect dilution]. 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	vaccine neutralization efficacy	Gong et al. (2021)	'G142D', 'E154K', 'L452R', 'D614G', 'P681R', 'Q1071H'	1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	vaccine neutralization efficacy	Gong et al. (2021)	'L452R', 'D614G'	1.4x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	vaccine neutralization efficacy	Tada et al. (2021)	'L452R', 'D614G'	Pseudotyped viruses for B.1.617 was 4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 5-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	vaccine neutralization efficacy	Wilhelm et al. (2021)	'G142D', 'E154K', 'L452R', 'D614G', 'P681R', 'Q1071H'	Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	vaccine neutralization efficacy	Yadav et al. (2021)	'G142D', 'E154K', 'L452R', 'D614G', 'P681R', 'Q1071H'	Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	vaccinee plasma binding	Gong et al. (2021)	'L452R', 'D614G'	This variant combination (representing lineage B.1.617) showed a 1.30x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.18x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred fro common knowledge]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.E484Q	c.G1450C	p.E484Q			23012	S	S	MISSENSE	407	407						0	407	G	C	B.1.617.1	viral load	Yadav et al. (2021)	'L452R', 'P681R'	In 9 infected hamsters each for B.1 and B.1.617.1, no significant change in viral load or subgenomic RNA levels were detected. 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.F53F	c.C159T	p.F53F			26681	M	M	SILENT	407	407						27	380	C	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.F924F	c.C2772T	p.F924F			3037	orf1ab	ORF1ab	SILENT	407	407			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	407	C	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	388	407	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	388	G	A	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'E154K', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]"	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	388	407	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	388	G	A	B.1.617.1	convalescent plasma escape	Wilhelm et al. (2021)	'E154K', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	388	407	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	388	G	A	B.1.617.1	monoclonal antibody serial passage escape	McCallum et al. (2021)		Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28, S2X333	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	388	407	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	388	G	A	B.1.617.1	monoclonal antibody serial passage escape	Suryadevara et al. (2021)		Selected twice in passage with mAb COV2-2489.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	388	407	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	388	G	A	B.1.617.1	trafficking	Esclera et al. (2021)	'E154K', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site). 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	388	407	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	388	G	A	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'E154K', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	388	407	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	388	G	A	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'T95I', 'E154K', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	"Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	388	407	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	388	G	A	B.1.617.1	vaccine neutralization efficacy	Gong et al. (2021)	'E154K', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	388	407	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	388	G	A	B.1.617.1	vaccine neutralization efficacy	Wilhelm et al. (2021)	'E154K', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	388	407	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	388	G	A	B.1.617.1	vaccine neutralization efficacy	Yadav et al. (2021)	'E154K', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.G5530C	c.G16588T	p.G5530C			16852	orf1ab	ORF1ab	MISSENSE	407	407			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	28	379	G	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.H5290H	c.C15870T	p.H5290H			16134	orf1ab	ORF1ab	SILENT	407	407			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	69	338	C	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.I82S	c.T245G	p.I82S			26767	M	M	MISSENSE	407	407						28	379	T	G	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.K6711R	c.A20132G	p.K6711R			20396	orf1ab	ORF1ab	MISSENSE	407	407			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	1	406	A	G	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L2742L	c.G8226A	p.L2742L			8491	orf1ab	ORF1ab	SILENT	407	407			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	69	338	G	A	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'E484Q', 'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617) showed a 1.85x increase  in binding (KD) relative to D614G. [exact variant list not provided in manuscript, is inferred fro common knowledge]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'G142D', 'E154K', 'E484Q', 'D614G', 'P681R', 'Q1071H'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]"	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	ACE2 receptor binding affinity	Motozono et al. (2021)		~1.7-fold increase in binding affinity vs wild type.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	T cell evasion	Motozono et al. (2021)		L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	antibody epitope effects	Li et al. (2020)		Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	antibody epitope effects	Liu et al. (2021)		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	antibody epitope effects	McCallum et al. (2021)		10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	antibody epitope effects	Sun et al. (2021)		~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	convalescent plasma binding	Gong et al. (2021)	'D614G'	2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	convalescent plasma binding	Gong et al. (2021)	'E484Q', 'D614G'	This variant combination (representing lineage B.1.617) showed a 1.22x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred fro common knowledge]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	convalescent plasma escape	Alenquer et al. (2021)		Observed ~2x decrease on average in 16 health workers' convalescent sera.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	convalescent plasma escape	Liu et al. (2021)		Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	convalescent plasma escape	Tada et al. (2021)	'E484Q', 'D614G'	Pseudotyped viruses for B.1.617 was 2.3-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	convalescent plasma escape	Wilhelm et al. (2021)	'D614G'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	convalescent plasma escape	Wilhelm et al. (2021)	'G142D', 'E154K', 'E484Q', 'D614G', 'P681R', 'Q1071H'	Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	gene expression increase	Starr et al. (2020)		Experimentally, Spike gene expression increased 0.32 fold	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	monoclonal antibody serial passage escape	Greaney et al. (2020)		Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	monoclonal antibody serial passage escape	Starr et al. (2021)		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	monoclonal antibody serial passage escape	Wang et al. (2021)		Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	pharmaceutical effectiveness	Engelhart et al. (2021)		Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	pharmaceutical effectiveness	McCallum et al. (2021)		Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	symptom prevalence	Yadav et al. (2021)	'E484Q', 'P681R'	Gross examination of 3+3 hamster lung specimens showed pronounced congestion and hemorrhages on days 5 and 7 post-infection in the case of the B.1.617.1 as compared with the B.1. The lung lesions with  the B.1 variant were minimal to mild whereas with B.1.617.1 they were moderate. For B.1 pneumonic changes were minimal to mild (inflammatory cell infiltration, focal consolidation and mild congestion). The pronounced changes (moderate to severe) with mononuclear infiltration in the alveolar interstitial space, interstitial septal thickening, consolidation and pneumocyte hyperplasia were observed with B.1.617.1 variant consistently.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	trafficking	Deng et al. (2021)		We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	trafficking	Esclera et al. (2021)	'G142D', 'E154K', 'E484Q', 'D614G', 'P681R', 'Q1071H'	~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site). 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	trafficking	Ferriera et al (2021)		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistucally significant, but error bars say otherwise in Figure 4]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	trafficking	Motozono et al. (2021)		Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	transmissibility	Tada et al. (2021)	'D614G'	Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	transmissibility	Tada et al. (2021)	'E484Q', 'D614G'	The combination caused a 3-fold increase in infectivity relative to D614G wild type. [compare to 3.5x for L452R alone]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	transmissibility	Tada et al. (2021)	'E484Q', 'P681R', 'D614G'	Normalized for particle number, on ACE2.293T cells showed that the B.1.617 spike protein was >2-fold increase in infectivity relative to D614G wild type.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'G142D', 'E154K', 'E484Q', 'D614G', 'P681R', 'Q1071H'	Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'T95I', 'G142D', 'E154K', 'E484Q', 'D614G', 'P681R', 'Q1071H'	"Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	vaccine neutralization efficacy	Ferreira et al. (2021)		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	vaccine neutralization efficacy	Ferreira et al. (2021)	'E484Q'	Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484Q had a ~5x drop in neutralization (vs ~10x for E484K). When E484Q and L452R were combined, the fold change was significant, but similar to that of L452R alone (~2x), suggesting no evidence for an additive effect [perhaps even E484Q effect dilution]. 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	vaccine neutralization efficacy	Gong et al. (2021)	'E484Q', 'D614G'	1.4x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	vaccine neutralization efficacy	Gong et al. (2021)	'G142D', 'E154K', 'E484Q', 'D614G', 'P681R', 'Q1071H'	1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	vaccine neutralization efficacy	Jacobson et al. (2021)		The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	vaccine neutralization efficacy	Tada et al. (2021)	'E484Q', 'D614G'	Pseudotyped viruses for B.1.617 was 4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 5-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	vaccine neutralization efficacy	Wilhelm et al. (2021)	'D614G'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	vaccine neutralization efficacy	Wilhelm et al. (2021)	'G142D', 'E154K', 'E484Q', 'D614G', 'P681R', 'Q1071H'	Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	vaccine neutralization efficacy	Yadav et al. (2021)	'G142D', 'E154K', 'E484Q', 'D614G', 'P681R', 'Q1071H'	Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	vaccinee plasma binding	Gong et al. (2021)	'E484Q', 'D614G'	This variant combination (representing lineage B.1.617) showed a 1.30x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.18x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred fro common knowledge]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	viral load	Yadav et al. (2021)	'E484Q', 'P681R'	In 9 infected hamsters each for B.1 and B.1.617.1, no significant change in viral load or subgenomic RNA levels were detected. 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	407	407						0	407	T	G	B.1.617.1	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type) 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.L5580F	c.C16738T	p.L5580F			17002	orf1ab	ORF1ab	MISSENSE	407	407			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	166	241	C	T	B.1.617.1					False	False	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.M5753I	c.G17259T	p.M5753I			17523	orf1ab	ORF1ab	MISSENSE	407	407			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	407	G	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.N43Y	c.A127T	p.N43Y			27520	ORF7a	ORF7a	MISSENSE	401	407						69	332	A	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P4715L	c.C14144T	p.P4715L			14408	orf1ab	ORF1ab	MISSENSE	407	407			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	407	C	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'Q1071H'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]"	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	convalescent plasma escape	Wilhelm et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'Q1071H'	Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	symptom prevalence	Yadav et al. (2021)	'L452R', 'E484Q'	Gross examination of 3+3 hamster lung specimens showed pronounced congestion and hemorrhages on days 5 and 7 post-infection in the case of the B.1.617.1 as compared with the B.1. The lung lesions with  the B.1 variant were minimal to mild whereas with B.1.617.1 they were moderate. For B.1 pneumonic changes were minimal to mild (inflammatory cell infiltration, focal consolidation and mild congestion). The pronounced changes (moderate to severe) with mononuclear infiltration in the alveolar interstitial space, interstitial septal thickening, consolidation and pneumocyte hyperplasia were observed with B.1.617.1 variant consistently.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	trafficking	Esclera et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'Q1071H'	~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site). 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	trafficking	Maaroufi (2021)		This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry). [Inference from similar positively charged substitution P681H actually described in the work]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	trafficking	Tada et al. (2021)	'D614G'	Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	transmissibility	Tada et al. (2021)	'L452R', 'E484Q', 'D614G'	Normalized for particle number, on ACE2.293T cells showed that the B.1.617 spike protein was >2-fold increase in infectivity relative to D614G wild type.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'Q1071H'	Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'T95I', 'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'Q1071H'	"Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	vaccine neutralization efficacy	Gong et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'Q1071H'	1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	vaccine neutralization efficacy	Wilhelm et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'Q1071H'	Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	vaccine neutralization efficacy	Yadav et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'Q1071H'	Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	viral load	Yadav et al. (2021)	'L452R', 'E484Q'	In 9 infected hamsters each for B.1 and B.1.617.1, no significant change in viral load or subgenomic RNA levels were detected. 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.P681R	c.C2042G	p.P681R			23604	S	S	MISSENSE	407	407						0	407	C	G	B.1.617.1	virion structure	Tada et al. (2021)		The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing. [PG: Inferred by conservative AA substitution of described P681H]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.Q1071H	c.A3213T	p.Q1071H			24775	S	S	MISSENSE	406	407						0	406	A	T	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'P681R'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]"	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.Q1071H	c.A3213T	p.Q1071H			24775	S	S	MISSENSE	406	407						0	406	A	T	B.1.617.1	convalescent plasma escape	Wilhelm et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'P681R'	Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.Q1071H	c.A3213T	p.Q1071H			24775	S	S	MISSENSE	406	407						0	406	A	T	B.1.617.1	trafficking	Esclera et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'P681R'	~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site). 	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.Q1071H	c.A3213T	p.Q1071H			24775	S	S	MISSENSE	406	407						0	406	A	T	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'P681R'	Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.Q1071H	c.A3213T	p.Q1071H			24775	S	S	MISSENSE	406	407						0	406	A	T	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'T95I', 'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'P681R'	"Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.Q1071H	c.A3213T	p.Q1071H			24775	S	S	MISSENSE	406	407						0	406	A	T	B.1.617.1	vaccine neutralization efficacy	Gong et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'P681R'	1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript]	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.Q1071H	c.A3213T	p.Q1071H			24775	S	S	MISSENSE	406	407						0	406	A	T	B.1.617.1	vaccine neutralization efficacy	Wilhelm et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'P681R'	Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.Q1071H	c.A3213T	p.Q1071H			24775	S	S	MISSENSE	406	407						0	406	A	T	B.1.617.1	vaccine neutralization efficacy	Yadav et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'P681R'	Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.R203M	c.G608T	p.R203M			28881	N	N	MISSENSE	407	407	caution	neighbour_linked				0	407	G	T	B.1.617.1	RNA binding	Syed et al. (2021)		Northern blot analysis of novel mutant virus-like-particles (VLPs) shows most increase in RNA content of any N mutation tested, suggesting that this mutation improves virus particle production (requisite RNA packaging signal binding site in nsp15/16 boundary is included in the VLP).	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.S26L	c.C77T	p.S26L			25469	ORF3a	ORF3a	MISSENSE	407	407						0	407	C	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.S6713A	c.T20137G	p.S6713A			20401	orf1ab	ORF1ab	MISSENSE	407	407			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	21	386	T	G	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.T1567I	c.C4700T	p.T1567I			4965	orf1ab	ORF1ab	MISSENSE	407	407			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	407	C	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.T3646A	c.A10936G	p.T3646A			11201	orf1ab	ORF1ab	MISSENSE	407	407			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	407	A	G	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.T95I	c.C284T	p.T95I			21846	S	S	MISSENSE	405	407						28	377	C	T	B.1.617.1	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.T95I	c.C284T	p.T95I			21846	S	S	MISSENSE	405	407						28	377	C	T	B.1.617.1	convalescent plasma binding	Gong et al. (2021)	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.T95I	c.C284T	p.T95I			21846	S	S	MISSENSE	405	407						28	377	C	T	B.1.617.1	vaccine neutralization efficacy	Choi et al. (2021)	'G142D', 'E154K', 'L452R', 'E484Q', 'D614G', 'P681R', 'Q1071H'	"Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster."	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.T95I	c.C284T	p.T95I			21846	S	S	MISSENSE	405	407						28	377	C	T	B.1.617.1	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.V82A	c.T245C	p.V82A			27638	ORF7a	ORF7a	MISSENSE	401	407						0	401	T	C	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
p.Y1064Y	c.C3192T	p.Y1064Y			3457	orf1ab	ORF1ab	SILENT	407	407			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	407	C	T	B.1.617.1					False	True	Kappa	VUM	4-Apr-2021		20-Sep-2021
